Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,181.0
-17.6 (-0.55%)

 

  • STI Straits Times Index
    3,181.0
    -17.6 (-0.55%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,531.2
    -3.8 (-0.25%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,308.8
    -300.3 (-1.09%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,039.7
    9.5 (0.31%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,386.7
    -92.4 (-0.39%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    5,882.3
    -60.2 (-1.01%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,078.9M
  • Value: 1,171.0M
  • Rise: 88
  • Fall: 225
  • Unch: 501

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
AusGroup^0.048-0.004
Rex Intl0.193-0.007
Ntegrator Intl0.008-0.002
Medtecs Intl0.097+0.001
Ley Choon0.019+0.001
YZJ Shipbldg SGD1.040-
Singtel3.100-0.030
ComfortDelGro2.020-0.030
Genting Sing0.880-
Dyna-Mac0.134-0.016

World Indices

World Indices
Name Last Change
Nasdaq 9,576.6 -174.4
HSI 27,308.8
HSCEI 10,790.8
Jakarta 5,882.3
Nikkei 225 23,386.7 -92.4
SSE Comp 3,039.7
Shanghai A 3,185.3
Shanghai B 244.9
KOSPI 2,162.8

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

CELLMID LIMITED CELLMID
Updated on 21 Feb 2020 (End of trading day)
Last (AUD): 0.185 Change: - High: 0.185 Remarks: -
Change (%): - Low: 0.185
Open 0.185 Yesterday's Close 0.185
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 10,078 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (AUD) a -0.06118 Trailing EPS (AUD) e -0.06118 NAV (AUD) b 0.0606
PE a - Trailing PE f - Price / NAV b 3.0528
Dividend (AUD) d - Cash In Hand (AUD) g 0.0319 Issued & Paid-up Shares c 96,596,900
Dividend Yield (%) d - Price / Cash In Hand g 5.799 Treasury Shares h -
Beta - 75 Daysi -0.353 R-Squared - 75 Days(%)i 0.36 Market Cap (M) 17.870
Beta - 500 Daysi 0.144 R-Squared - 500 Days (%)i 0.07 Enterprise Value (M) 16.075
Piotroski F Score 4 Exchange Code CDY Par Value ( AUD ) n.a.
52 Weeks Volatility (%) 61.43 Free Float (%) -
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 21 Nov 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 30 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference CELLMID LIMITED ASX 17.870 - - 3.0528 -
Industry Pharmaceuticals: Major ASX 77.507 - - 7.0580 -
Local Peer STARPHARMA HOLDINGS LIMITED ASX 454.501 - - 10.7206 -
Local Peer AFT PHARMACEUTICALS LTD ASX 301.658 - 29.805 22.2541 -
Local Peer PYC THERAPEUTICS LIMITED ASX 202.269 - - 32.8571 -
Local Peer PALLA PHARMA LTD ASX 107.056 - - 2.3481 -
Local Peer ONCOSIL MEDICAL LIMITED ASX 104.067 - - 9.7633 -
Local Peer MEDLAB CLINICAL LIMITED ASX 71.133 - - 4.7287 -
Local Peer RECCE PHARMACEUTICALS LTD ASX 64.233 - - -159.6774 -
Local Peer INVION LTD ASX 55.006 - - 10.0000 -
Local Peer RACE ONCOLOGY LTD ASX 52.390 - - 10.3672 -
Local Peer PHARMAXIS ASX 43.420 - - 8.5938 -
Local Peer NOXOPHARM LTD ASX 41.216 - - -435.7143 -
Local Peer ACRUX ASX 30.127 - - 1.3730 -
Other Local Peers EXOPHARM LTD (ASX), IMMURON LIMITED (ASX), TALI DIGITAL LIMITED (ASX), CRESO PHARMA LTD (ASX), FARMAFORCE LTD (ASX), SUDA PHARMACEUTICALS LTD (ASX), FIJI KAVA LTD (ASX), TBG DIAGNOSTICS LTD (ASX)
Global Peer JOHNSON & JOHNSON NYSE 395,023.570 25.824 26.128 6.6423 2.386
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 244,549.289 19.347 20.805 - 1.741
Global Peer MERCK & CO INC NYSE 209,635.993 33.703 21.298 - 2.461
Global Peer PFIZER INC NYSE 197,678.766 17.726 12.148 - 3.991
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 153,848.533 31.270 44.736 - 1.699
Global Peer ABBVIE INC NYSE 140,428.747 24.824 17.914 -17.1842 4.160
Global Peer ELI LILLY AND COMPANY NYSE 135,844.499 42.031 29.290 52.1095 1.751
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NYSE 131,664.643 61.201 98.035 10.0300 2.637
Global Peer SANOFI SPON ADR ECH REP 1/2 ORD EUR2 LEVEL II NASDAQ 127,516.037 25.026 40.685 1.9276 2.257
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 118,924.456 19.451 20.352 13.7463 1.781
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), WUXI APPTEC (HKEx), HANSOH PHARMA (HKEx), SINOPHARM (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), CHINARES PHARMA (HKEx), INNOVENT BIO-B (HKEx), SH PHARMA (HKEx), BAIYUNSHAN PH (HKEx), REPLIGEN CORP (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), HUTCHISON CHINA MEDITECH SPON ADS EACH REPR 5 ORD SHS (NASDAQ), CMS (HKEx), ALLAKOS INC (NASDAQ), TRAD CHI MED (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), SSY GROUP (HKEx), JUNSHI BIO-B (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), HENLIUS-B (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), FORTY SEVEN INC (NASDAQ), CANSINOBIO-B (HKEx), CHINAGRANDPHARM (HKEx), RA PHARMACEUTICALS INC (NASDAQ), PRINCIPIA BIOPHARMA INC (NASDAQ), ZYMEWORKS INC (NYSE), TURNING POINT THERAPEUTICS INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), TRICIDA INC (NASDAQ), AKCEA THERAPEUTICS INC (NASDAQ), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), TONGRENTANGCM (HKEx), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), CSTONE PHARMA-B (HKEx), Y-MABS THERAPEUTICS INC (NASDAQ), CKLIFE SCIENCES (HKEx), UNITED LAB (HKEx), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), OPKO HEALTH INC (NASDAQ), ATHENEX INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), PETIQ INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), PROVENTION BIO INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), SHINEWAY PHARM (HKEx), G1 THERAPEUTICS IN (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), AC IMMUNE SA (NASDAQ), IGBB (Bursa), MILESTONE PHARMACEUTICALS INC (NASDAQ), HUA MEDICINE-B (HKEx), NEOLEUKIN THERAPEUTICS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), FUSEN PHARM (HKEx), SATSUMA PHARMACEUTICALS INC (NASDAQ), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), 89BIO INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), DURECT CORP (NASDAQ), BSTEAD (Bursa), GALERA THERAPEUTICS INC (NASDAQ), UROVANT SCIENCES LTD (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), GRITSTONE ONCOLOGY INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), LANNETT CO INC (NYSE), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), EVOLUS INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), AMAG PHARMACEUTICS INC (NASDAQ), Kimia Farma (Persero) Tbk. (IDX), HOOKIPA PHARMA INC (NASDAQ), VERU INC (NASDAQ), TOT BIOPHARM-B (HKEx), OCULAR THERAPEUTIX INC (NASDAQ), DAWNRAYS PHARMA (HKEx), SOL GEL TECHNOLOGIES LTD (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), BIOMX INC (NYSE American), SPERO THERAPEUTICS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), ARTARA THERAPEUTICS INC (NASDAQ), AKORN INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), GENPREX INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), MUSTANG BIO INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), MILLENDO THERAPEUTICS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), CH BIOTECH SER (HKEx), OBSEVA SA (NASDAQ), LIQUIDIA TECHNOLOGIES INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), ZHONGZHIPHARM (HKEx), NEUBASE THERAPEUTICS INC (NASDAQ), MENLO THERAPEUTICS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), PHARMA (Bursa), CLEARSIDE BIOMEDICAL INC (NASDAQ), ESSA PHARMA INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), NC HEALTHCARE (HKEx), ASSERTIO THERAPEUTICS INC (NASDAQ), PAK FAH YEOW (HKEx), CHARMACY PHAR (HKEx), TREVI THERAPEUTICS INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), NEW RAY MEDIC (HKEx), IMMUNIC INC (NASDAQ), IX Biopharma (SGX), BAUDAX BIO INC (NASDAQ), MEDIWOUND LTD (NASDAQ), KOTRA (Bursa), EYENOVIA INC (NASDAQ), Merck Tbk. (IDX), NEP INTERLONG (HKEx), CNS PHARMACEUTICALS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), WAI YUEN TONG (HKEx), ENTERA BIO LTD (NASDAQ), Phapros Tbk. (IDX), ACER THERAPEUTICS INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), Hyphens Pharma (SGX), HOTH THERAPEUTICS INC (NASDAQ), NOVA (Bursa), PURAPHARM (HKEx), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), ANNOVIS BIO INC (NYSE American), EXTRAWELL PHAR (HKEx), MANNATECH INC (NASDAQ), SANAI HEALTH GP (HKEx), MOLECULIN BIOTECH INC (NASDAQ), JCT (SET), BIOHLDG (Bursa), IP (SET), EDESA BIOTECH INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), TELIGENT INC NEW (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), SINOLIFE UTD (HKEx), PASHUN INT'L (HKEx), PROPHASE LABS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), SPRING BANK PHARMACEUTICALS INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), NOVAN INC (NASDAQ), SUNZEN (Bursa), KITOV PHARMA LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), APPLIED DNA SCIENCES INC (NASDAQ), NOVUS THERAPEUTICS INC (NASDAQ), Merck Sharp Dohme Pharma Tbk. (IDX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.005
-2.63 %
10 Days --0.010
-5.13 %
20 Days --0.045
-19.57 %
Medium Term Return 3 Months --0.050
-21.28 %
6 Months --0.035
-15.91 %
1 Year --0.075
-28.85 %
Long Term Return 2 Years --0.335
-64.42 %
3 Years --0.495
-72.79 %
5 Years --0.315
-63.00 %
Annualised Return Annualised --
-18.03 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.165 - 0.285 Change From 1 Year Low +0.020 % Change From 1 Year Low (%) +12.12
Change From 1 Year High -0.100 % Change From 1 Year High (%) -35.09
2 Years Range 0.165 - 0.570 Change From 2 Years Low +0.020 % Change From 2 Years Low (%) +12.12
Change From 2 Years High -0.385 % Change From 2 Years High (%) -67.54
5 Years Range 0.019 - 0.880 Change From 5 Years Low +0.166 % Change From 5 Years Low (%) +873.68
Change From 5 Years High -0.695 % Change From 5 Years High (%) -78.98
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Cellmid Ltd. operates as a biotechnology company, which engages in the development and marketing of therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. It operates through the following segments: research and development of diagnostics and therapeutics; and research, development and marketing of hair care products. The company was founded on October 8, 2004 and is headquartered in Sydney, Australia.

Historical Price Data

Date Open High Low Close Volume VWAP
21 Feb 2020 0.185 0.185 0.185 0.185 10,078 -
20 Feb 2020 0.185 0.185 0.180 0.185 99,966 -
19 Feb 2020 0.190 0.190 0.190 0.190 - -
18 Feb 2020 0.195 0.195 0.190 0.190 28,361 -
17 Feb 2020 0.190 0.190 0.190 0.190 - -
14 Feb 2020 0.190 0.190 0.190 0.190 - -
13 Feb 2020 0.190 0.190 0.190 0.190 244,785 -
12 Feb 2020 0.190 0.190 0.190 0.190 - -
11 Feb 2020 0.190 0.190 0.190 0.190 13,782 -
10 Feb 2020 0.195 0.195 0.190 0.190 38,693 -
07 Feb 2020 0.200 0.205 0.195 0.195 68,348 -
06 Feb 2020 0.200 0.200 0.195 0.195 40,764 -
05 Feb 2020 0.200 0.205 0.200 0.200 51,474 -
04 Feb 2020 0.195 0.195 0.195 0.195 182,168 -
03 Feb 2020 0.205 0.205 0.200 0.200 274,615 -
31 Jan 2020 0.210 0.210 0.210 0.210 47,600 -
30 Jan 2020 0.225 0.225 0.210 0.210 231,231 -
29 Jan 2020 0.220 0.220 0.220 0.220 19,033 -
28 Jan 2020 0.225 0.225 0.225 0.225 1,674 -
24 Jan 2020 0.230 0.230 0.230 0.230 17,582 -
23 Jan 2020 0.225 0.230 0.225 0.230 56,108 -
22 Jan 2020 0.225 0.230 0.225 0.230 24,750 -
Summary
Current 2 Weeks
(10 Feb 2020 to 21 Feb 2020)
0.195 0.195 0.180 0.185 435,665 -
Previous 2 Weeks
(24 Jan 2020 to 07 Feb 2020)
0.230 0.230 0.180 0.195 934,489 -
4 Weeks from
(24 Dec 2019 to 23 Jan 2020)
0.220 0.220 0.180 0.230 969,062 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.